Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer

INTRODUCTION: The treatment of lung cancer is not defined in the third-line setting and remains an unanswered question. Erlotinib is the only drug approved in the third-line setting. With the introduction of effective first- and second-line therapies, more and more patients warrant an effective thir...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:South Asian J Cancer
Autors principals: Noronha, Vanita, Pande, Nikhil, Joshi, Amit, Patil, Vijay, Trivedi, Vaishakhi, Chougule, Anuradha, Janu, Amit, Mahajan, Abhishek, Talreja, Vikas, Prabhash, Kumar
Format: Artigo
Idioma:Inglês
Publicat: Wolters Kluwer - Medknow 2020
Matèries:
ORIGINAL ARTICLE: Lung Cancers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6956591/
https://ncbi.nlm.nih.gov/pubmed/31956622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_28_19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars